open access
Increased Rho kinase activity predicts worse cardiovascular outcome in ST-segment elevation myocardial infarction patients
open access
Abstract
Background: Few clinical studies have assessed Rho kinase (ROCK) in patients with diabetes mellitus (DM) and ST-segment elevation myocardial infarction (STEMI). This study aimed to determine whether ROCK activity in circulating leukocytes is increased in STEMI patients with DM and whether ROCK activity predicts the onset of cardiovascular events.
Methods: Blood samples were collected from 60 STEMI patients, divided into non-diabetes mellitus (NDM) and DM groups. Main outcome measures were all-cause mortality, readmission for acute coronary syndrome (ACS), congestive heart failure (CHF), or stroke from presentation to approximately 5 years (mean: 41.3 ± 19.6 months; range: 3–60 months).
Results: Compared with the NDM group (n = 34), ROCK1 activity was greater in the DM group (n = 26) (33.14 ± 11.31 vs. 26.24 ± 11.06, p = 0.021), while ROCK2 activity was not different between the groups. There occurred 3 deaths, and 10 readmissions with ACS, 4 with CHF and 2 with stroke during the follow-up period. Patients with a high ROCK1 activity on admission had a 3-fold risk of cardiovascular events (RR 3.15, 95% CI 1.04–9.58) compared with those with low ROCK1 activity. Patients with history of stroke had almost a 4-fold risk of cardiovascular events (RR 3.74; 95% CI 1.02–13.80).
Conclusions: ROCK1 activity was increased in STEMI patients with DM, which suggests that ROCK1 activity may be a useful diagnostic and prognostic marker of cardiovascular events for these patients. ROCK1 activity might help identify a subset of STEMI patients at particularly high risk.
Abstract
Background: Few clinical studies have assessed Rho kinase (ROCK) in patients with diabetes mellitus (DM) and ST-segment elevation myocardial infarction (STEMI). This study aimed to determine whether ROCK activity in circulating leukocytes is increased in STEMI patients with DM and whether ROCK activity predicts the onset of cardiovascular events.
Methods: Blood samples were collected from 60 STEMI patients, divided into non-diabetes mellitus (NDM) and DM groups. Main outcome measures were all-cause mortality, readmission for acute coronary syndrome (ACS), congestive heart failure (CHF), or stroke from presentation to approximately 5 years (mean: 41.3 ± 19.6 months; range: 3–60 months).
Results: Compared with the NDM group (n = 34), ROCK1 activity was greater in the DM group (n = 26) (33.14 ± 11.31 vs. 26.24 ± 11.06, p = 0.021), while ROCK2 activity was not different between the groups. There occurred 3 deaths, and 10 readmissions with ACS, 4 with CHF and 2 with stroke during the follow-up period. Patients with a high ROCK1 activity on admission had a 3-fold risk of cardiovascular events (RR 3.15, 95% CI 1.04–9.58) compared with those with low ROCK1 activity. Patients with history of stroke had almost a 4-fold risk of cardiovascular events (RR 3.74; 95% CI 1.02–13.80).
Conclusions: ROCK1 activity was increased in STEMI patients with DM, which suggests that ROCK1 activity may be a useful diagnostic and prognostic marker of cardiovascular events for these patients. ROCK1 activity might help identify a subset of STEMI patients at particularly high risk.
Keywords
Rho kinase activity, diabetes mellitus, ST-segment elevation myocardial infarction, circulating leukocytes, insulin resistance
About this articleTitle
Increased Rho kinase activity predicts worse cardiovascular outcome in ST-segment elevation myocardial infarction patients
Journal
Issue
Pages
456-464
Published online
2016-06-16
Page views
1659
Article views/downloads
1323
DOI
10.5603/CJ.a2016.0031
Pubmed
Bibliographic record
Cardiol J 2016;23(4):456-464.
Keywords
Rho kinase activity
diabetes mellitus
ST-segment elevation myocardial infarction
circulating leukocytes
insulin resistance
Authors
Xiaohui Li
Xing Wu
Hongwei Li
Hui Chen
Yongliang Wang
Weiping Li
Xiaosong Ding
Xu Hong
